Cancer testis antigen 55 deficiency attenuates colitis-associated colorectal cancer by inhibiting NF-κB signaling

Zhao, Huan; Pan, Wen-Ming; Zhang, Huihui; Song, Yang; Chen, Jie; Xiang, Ying; Gu, Bingxin; Li, Shangze; Du, Runlei; Zhang, Xiaodong

doi:10.1038/s41419-019-1537-x

Cited by 10 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is highly expressed in HCC and related to the invasive biological behavior of HCC cells, but the specific mechanism is not fully understood ( Pan et al, 2014 ). CT55 is also a member of the cancer testicular antigen family, and studies have found that CT55 deficiency inhibits the NF-KB signaling pathway, thereby attenuating colitis-associated cancers ( Zhao et al, 2019 ). Studies have also shown that CT55 regulates mitochondrial activity and thus maintains the proliferation of cancer cells ( Aurrière et al, 2022 ).…”

Section: Discussionmentioning

confidence: 99%

Identification of Novel Characteristics in TP53-Mutant Hepatocellular Carcinoma Using Bioinformatics

Yang

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

Background: TP53 mutations are the most frequent mutations in hepatocellular carcinoma (HCC) and affect the occurrence and development of this cancer type. Therefore, it is essential to clarify the function and mechanism of TP53 mutations in HCC.Methods: We performed a sequence of bioinformatic analyses to elucidate the characteristics of TP53 mutations in HCC. We downloaded the data of hepatocellular carcinoma from The Cancer Genome Atlas database and used different R packages for serial analyses, including gene mutation analysis, copy number variation analysis, analysis of the tumor mutational burden and microsatellite instability, differential gene expression analysis, and functional enrichment analysis of TP53 mutations, and performed gene set enrichment analysis. We established a protein-protein interaction network using the STRING online database and used the Cytoscape software for network visualization, and hub gene screening. In addition, we performed anticancer drug sensitivity analysis using data from the Genomics of Drug Sensitivity in Cancer. Immune infiltration and prognosis analyses were also performed.Results: Missense mutations accounted for a great proportion of HCC mutations, the frequency of single nucleotide polymorphisms was high, and C > T was the most common form of single nucleotide variations. TP53 had a mutation rate of 30% and was the most commonly mutated gene in HCC. In the TP53 mutant group, the tumor mutational burden (p < 0.001), drug sensitivity (p < 0.05), ESTIMATE score (p = 0.038), and stromal score (p < 0.001) dramatically decreased. The Cytoscape software screened ten hub genes, including CT45A1, XAGE1B, CT55, GAGE2A, PASD1, MAGEA4, CTAG2, MAGEA10, MAGEC1, and SAGE1. The prognostic model showed a poor prognosis in the TP53 mutation group compared with that in the wild-type group (overall survival, p = 0.023). Univariate and multivariate cox regression analyses revealed that TP53 mutation was an independent risk factor for the prognosis of HCC patients (p <0.05). The constructed prognostic model had a favorable forecast value for the prognosis of HCC patients at 1 and 3 years (1-year AUC = 0.752, 3-years AUC = 0.702).Conclusion: This study further deepened our understanding of TP53-mutated HCC, provided new insights into a precise individualized therapy for HCC, and has particular significance for prognosis prediction.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of Novel Characteristics in TP53-Mutant Hepatocellular Carcinoma Using Bioinformatics

Yang

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

show abstract

“…Colorectal cancer tissues and paired noncancerous tissues were obtained from Tongji Medical College of Huazhong University of Science and Technology in a previous study. 24 None of the patients received chemotherapy prior to colectomy. Written informed consent forms were obtained from all patients.…”

Section: Methodsmentioning

confidence: 99%

PTPN18 promotes colorectal cancer progression by regulating the c-MYC-CDK4 axis

Huang

et al. 2021

Genes & Diseases

Self Cite

View full text Add to dashboard Cite

Protein tyrosine phosphatase non-receptor type 18 (PTPN18) is often highly expressed in colorectal cancer (CRC), but its role in this disease remains unclear. We demonstrated that PTPN18 overexpression promotes growth and tumorigenesis in CRC cells and that PTPN18 deficiency yields the opposite results in vitro . Moreover, a xenograft assay showed that PTPN18 deficiency significantly inhibited tumorigenesis in vivo . PTPN18 activated the MYC signaling pathway and enhanced CDK4 expression, which is tightly associated with the cell cycle and proliferation in cancer cells. Finally, we found that MYC interacted with PTPN18 and increased the protein level of MYC. In conclusion, our results suggest that PTPN18 promotes CRC development by stabilizing the MYC protein level, which in turn activates the MYC-CDK4 axis. Thus, PTPN18 could be a novel therapeutic target in the future.

show abstract

“…Moreover, according to research, CT55 functions as a stimulator of nuclear factor-kB (NF-kB) signaling induced by tumor necrosis factor (TNF)-a by binding to the IkB kinase complex. Deficiency of CT55 suppresses the development of colitis-associated CRC (62).…”

Section: Tumorigenesis Development and Metastasismentioning

confidence: 99%

Cancer/testis antigens: promising immunotherapy targets for digestive tract cancers

Yang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Digestive tract cancers, including esophageal, gastric, and colorectal cancers, are the major cause of death among cancer patients worldwide due to the heterogeneity of cancer cells, which limits the effectiveness of traditional treatment methods. Immunotherapy represents a promising treatment strategy for improving the prognosis of patients with digestive tract cancers. However, the clinical application of this approach is limited by the absence of optimal targets. Cancer/testis antigens are characterized by low or absent expression in normal tissues, but high expression in tumor tissues, making them an attractive target for antitumor immunotherapy. Recent preclinical trials have shown promising results for cancer/testis antigen-targeted immunotherapy in digestive cancer. However, practical problems and difficulties in clinical application remain. This review presents a comprehensive analysis of cancer/testis antigens in digestive tract cancers, covering their expression, function, and potential as an immunotherapy target. Additionally, the current state of cancer/testis antigens in digestive tract cancer immunotherapy is discussed, and we predict that these antigens hold great promise as an avenue for breakthroughs in the treatment of digestive tract cancers.

show abstract

Cancer testis antigen 55 deficiency attenuates colitis-associated colorectal cancer by inhibiting NF-κB signaling

Cited by 10 publications

References 30 publications

Identification of Novel Characteristics in TP53-Mutant Hepatocellular Carcinoma Using Bioinformatics

Identification of Novel Characteristics in TP53-Mutant Hepatocellular Carcinoma Using Bioinformatics

PTPN18 promotes colorectal cancer progression by regulating the c-MYC-CDK4 axis

Cancer/testis antigens: promising immunotherapy targets for digestive tract cancers

Contact Info

Product

Resources

About